1. The pivotal role of ZNF384: driving the malignant behavior of serous ovarian cancer cells via the LIN28B/UBD axis.
- Author
-
Yang Y, He R, Li D, Mu T, Kuang Z, and Wang M
- Subjects
- Humans, Female, Animals, Cell Line, Tumor, Mice, Gene Expression Regulation, Neoplastic, Cell Movement genetics, Mice, Inbred BALB C, Cystadenocarcinoma, Serous genetics, Cystadenocarcinoma, Serous metabolism, Cystadenocarcinoma, Serous pathology, Ovarian Neoplasms genetics, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, RNA-Binding Proteins metabolism, RNA-Binding Proteins genetics, Mice, Nude, Cell Proliferation genetics
- Abstract
Zinc finger protein 384 (ZNF384) is a highly conserved transcribed gene associated with the development of multiple tumors, however, its role and mechanism in serous ovarian cancer (SOC) are unknown. We first confirmed that ZNF384 was abnormally highly expressed in SOC tissues by bioinformatics analysis and immunohistochemistry. We further used lentivirus packaging and transfection techniques to construct ZNF384 overexpression or knockdown cell lines, and through a series of cell function experiments, gradually verified that ZNF384 promoted a series of malignant behaviors of SOC cell proliferation, migration, and invasion. By establishing a xenotransplantation model in nude mice, it was confirmed that ZNF384 promoted the progress of SOC in vivo. Mechanistically, Overexpression of ZNF384 enhanced the transcriptional activity of Lin-28 homolog B (LIN28B), which promoted the malignant behavior of SOC cells. In addition, LIN28B could regulate the expression of the downstream factor ubiquitin D (UBD) in SOC cells, further promoting the development of SOC. This study shows that ZNF384 aggravates the malignant behavior of SOC cells through the LIN28B/UBD axis, which may be used as a diagnostic biomarker for patients with SOC., Competing Interests: Declarations Ethics approval All procedures involving human subjects were approved by Shengjing Hospital of China Medical University (Approval No. 2023PS426K), and animal experiments were performed with consent from the ethics committee of China Medical University (Approval No. CMU2023049). Consent for publication All authors have read the paper and agree that it can be published. Competing interests The authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF